Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Mondelez International (MDLZ) trades at $59.38, down 0.4% with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.73 beating expectations of $0.68. Revenue reached $38.54 billion in 2025, with an 8.86% net income margin and solid cash flow generation of $795 million. Analyst consensus remains strongly bullish with a $70.29 price target, representing 18% upside potential from current levels.

MDLZ presents a compelling investment case with consistent earnings outperformance, attractive dividend yield, and strong brand portfolio. However, investors face risks from cocoa cost volatility, competitive pressures, and margin compression. The stock's current valuation at 21.75 P/E offers reasonable entry point for long-term investors seeking defensive exposure in consumer staples with global growth potential.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.